...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Cutaneous Ischaemia Following Terlipressin Therapy for Hepatorenal Syndrome
【24h】

Cutaneous Ischaemia Following Terlipressin Therapy for Hepatorenal Syndrome

机译：特利加压素治疗肝肾综合征后的皮肤缺血

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hepatorenal Syndrome (HRS) is a potentially fatal complication of hepatic failure and portal hypertension. Among the various treatments available including octreotide, midodrine and albumin, the current standard of care for stable patients is terlipressin along with albumin. Although, terlipressin is considered safer than its parent molecule vasopressin, there have been reports of ischaemic side effects related to vasoconstrictor effects such as myocardial and mesenteric ischaemia. Cutaneous ischaemia has been reported in as few as 20 cases to date. We report the case of a gentleman who developed ischaemic skin lesions due to peripheral vasoconstriction following terlipressin thereapy for HRS and rapid reversal on discontinuing the drug. This and other similar cases highlight the need for larger studies exploring ischaemic side effects of terlipressin as well as close monitoring of patients for early detection of this side effect.
机译：肝肾综合征（HRS）是肝衰竭和门静脉高压症的潜在致命并发症。在包括奥曲肽，米多君和白蛋白在内的各种可用治疗方法中，目前稳定患者的护理标准是特利加压素和白蛋白。尽管特利加压素被认为比其母体分子加压素更安全，但已有报道与血管收缩作用有关的缺血性副作用，例如心肌和肠系膜缺血。迄今为止，已报道皮肤局部缺血只有20例。我们报道了一位绅士，他因特立加压素治疗HRS后因外周血管收缩而出现局部缺血性皮肤损害，并在停药后迅速逆转。该病例和其他类似病例强调需要进行更大的研究以探讨特利加压素的缺血性副作用，并密切监测患者以及早发现该副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号